Chest. 2025 May 29:S0012-3692(25)00673-7. doi: 10.1016/j.chest.2025.05.024. Online ahead of print.
ABSTRACT
BACKGROUND: Pulmonary hypertension (PH) is a high-risk finding in end-stage kidney disease (ESKD) and independently associated with increased mortality.
RESEARCH QUESTION: What is the relationship between pulmonary artery pressure (PAP) trajectories from pre- to post-kidney transplantation (KT), as well as the role of PH post-KT?
STUDY DESIGN AND METHODS: We analyzed retrospectively patients in the Veterans Affairs Healthcare System with PAP values both pre- and post-KT using echocardiography. The primary exposure was all-cause mortality, stratified by PH status (systolic PAP>35mmHg) into four groups: No-PH, New-PH, Resolved-PH and Persistent-PH. Findings were validated in the sex-balanced Vanderbilt University Medical System using echocardiography and right heart catheterization.
RESULTS: From N=631 patients (60±6 years; 96% male) in the primary cohort, N=364 (58%) there were N=231 (36.6%), N=184 (29.2%), N=133 (21.1%), and N=83 (13.1%) patients in the Persistent PH, Never PH, Resolved PH, and New PH groups, respectively. New-PH and Persistent-PH, were associated with a 51% (HR=1.51 [95%CI:1.06-2.15], p=0.023) and 37% (HR=1.37 [95%CI:1.03-1.82],p=0.029) increase in age- and sex-adjusted mortality risk compared to No-PH. Of all groups, Resolved PH was associated with the most favorable survival rate (adjusted HR=0.73 [95%CI:0.51-1.05], p=0.087; compared to No-PH). Longitudinal mortality risk increased continuously with ≥1 mmHg PAP increase from pre-KT to post-KT. Overall, we observed 21% increase in mortality risk per 10mmHg increment increase in echocardiographic sPAP from pre-KT to post-KT, adjusted for age, sex and baseline sPAP (HR=1.21 [95%CI:1.11-1.31],p<0.001), whereas a 10mmHg sPAP decrease was associated a 17% decrease in adjusted mortality risk (HR=0.83 [95%CI: 0.76-0.90], p<0.001). Results were reproducible in the validation cohort.
INTERPRETATION: In ESKD patients referred for KT as well as hemodynamic assessment, outcome is strongly associated with PAP trajectory. These data suggest PAP may be a novel biomarker for risk stratifying KT candidacy, supporting prospective ESKD studies investigating the role of PH in clinical decision-making.
PMID:40449880 | DOI:10.1016/j.chest.2025.05.024